Published in Mol Pharm on April 06, 2012
pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano (2013) 1.13
Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines (2014) 0.93
Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators. Pharmaceutics (2016) 0.83
Vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of mice. PLoS One (2012) 0.81
Enhancement of MHC-I antigen presentation via architectural control of pH-responsive, endosomolytic polymer nanoparticles. AAPS J (2014) 0.79
Incorporating gold nanoclusters and target-directed liposomes as a synergistic amplified colorimetric sensor for HER2-positive breast cancer cell detection. Theranostics (2017) 0.75
CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2001) 9.19
TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol (2004) 8.06
Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol (2005) 4.30
Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol (2004) 3.82
LacZ inducible, antigen/MHC-specific T cell hybrids. Int Immunol (1994) 3.47
The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol (2007) 3.44
Targeting the innate immune response with improved vaccine adjuvants. Nat Med (2005) 2.63
Triggering TLR signaling in vaccination. Trends Immunol (2005) 2.09
Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol (2000) 1.76
Cell-mediated immunity and the challenges for vaccine development. Trends Microbiol (2006) 1.70
Delivery of macromolecules into cytosol using liposomes containing hemolysin from Listeria monocytogenes. J Biol Chem (1996) 1.49
Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur J Immunol (2007) 1.33
CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol (2004) 1.32
Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev (2009) 1.28
CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev (2009) 1.27
Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol (2000) 1.24
CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol (2002) 1.23
Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim Biophys Acta (2002) 1.16
The cell biology of Listeria monocytogenes infection (escape from a vacuole). Ann N Y Acad Sci (1994) 1.02
Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J Immunol (2005) 1.01
Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine (1995) 1.00
The immunogenicity of CpG-antigen conjugates. Adv Drug Deliv Rev (2009) 0.97
CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans. J Clin Invest (2009) 0.96
Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells. Mol Pharm (2005) 0.94
Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin Biol Ther (2007) 0.93
Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes. Gene Ther (2003) 0.92
Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int Immunol (2009) 0.90
Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications. Immunol Rev (2004) 0.88
Cytosolic delivery of viral nucleoprotein by listeriolysin O-liposome induces enhanced specific cytotoxic T lymphocyte response and protective immunity. Mol Pharm (2004) 0.86
Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc Natl Acad Sci U S A (2002) 3.85
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev (2003) 3.25
Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med (2006) 2.57
A specific gene expression program triggered by Gram-positive bacteria in the cytosol. Proc Natl Acad Sci U S A (2004) 2.10
Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity (2011) 1.70
Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol (2003) 1.65
A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine (2003) 1.60
Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res (2002) 1.37
Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol (2006) 1.28
Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem (2003) 1.19
Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol (2002) 1.19
Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin Vaccine Immunol (2012) 1.17
Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim Biophys Acta (2002) 1.16
Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol (2002) 1.14
Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha. Immunology (2006) 1.09
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem (2008) 1.04
Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol (2004) 0.98
Enhanced gene delivery using disulfide-crosslinked low molecular weight polyethylenimine with listeriolysin o-polyethylenimine disulfide conjugate. J Control Release (2008) 0.97
Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm (2011) 0.96
Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol (2005) 0.96
Local and systemic effects of intranodally injected CpG-C immunostimulatory-oligodeoxyribonucleotides in macaques. J Immunol (2006) 0.96
Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand. J Leukoc Biol (2007) 0.95
Localization of protein kinase C epsilon to macrophage vacuoles perforated by Listeria monocytogenes cytolysin. Cell Microbiol (2007) 0.94
Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells. Mol Pharm (2005) 0.94
Induction of the gene encoding macrophage chemoattractant protein 1 by Orientia tsutsugamushi in human endothelial cells involves activation of transcription factor activator protein 1. Infect Immun (2002) 0.92
Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol Pharm (2013) 0.92
An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immun Ageing (2012) 0.92
Polymyxin B enhances ISS-mediated immune responses across multiple species. Cell Immunol (2004) 0.91
Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells. Nucleic Acids Res (2003) 0.91
Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol (2003) 0.90
Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J Biol Chem (2003) 0.89
Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers. Mol Pharm (2009) 0.88
Evolving strategies for the prevention of influenza infection: potential for multistrain targeting. BioDrugs (2006) 0.87
Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: Its utility in cytotoxic T lymphocyte-inducing DNA vaccine. J Control Release (2010) 0.86
Cytosolic delivery of viral nucleoprotein by listeriolysin O-liposome induces enhanced specific cytotoxic T lymphocyte response and protective immunity. Mol Pharm (2004) 0.86
Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. J Clin Invest (2015) 0.85
A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production. Eur J Immunol (2003) 0.83
A fluorescent hPept1 transporter substrate for uptake screening. Pharm Res (2003) 0.83
Immunostimulatory DNA as a vaccine adjuvant. Expert Rev Vaccines (2007) 0.83
Specificity of a prodrug-activating enzyme hVACVase: the leaving group effect. Mol Pharm (2010) 0.80
Conjugation of lipid and CpG-containing oligonucleotide yields an efficient method for liposome incorporation. Bioconjug Chem (2011) 0.79
Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution. Pharm Res (2003) 0.79
Enhanced plasmid DNA delivery using anionic LPDII by listeriolysin O incorporation. J Gene Med (2005) 0.77
Cytomegalovirus protease targeted prodrug development. Mol Pharm (2013) 0.77
Mutants of listeriolysin O for enhanced liposomal delivery of macromolecules. J Biotechnol (2013) 0.77
Puromycin-sensitive aminopeptidase: an antiviral prodrug activating enzyme. Antiviral Res (2009) 0.76
Local induction of a specific Th1 immune response by allergen linked immunostimulatory DNA in the nasal explants of ragweed-allergic subjects. Allergol Int (2009) 0.76
Design and characterization of novel recombinant listeriolysin O-protamine fusion proteins for enhanced gene delivery. Mol Pharm (2015) 0.76
Modulation of immunogenicity and allergenicity by controlling the number of immunostimulatory oligonucleotides linked to Amb a 1. J Allergy Clin Immunol (2006) 0.76
Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63). J Control Release (2002) 0.76
Visual detection of single-stranded target DNA using pyrroloquinoline-quinone-loaded liposomes as a tracer. Anal Biochem (2010) 0.75
Molecular pharmaceutics, a vision for the future. Mol Pharm (2005) 0.75
1656: MASSIVE LEFT VENTRICULAR ANEURYSM AFTER MYOCARDIAL INFARCTION. Crit Care Med (2016) 0.75
Absorbance-based assay for membrane disruption by antimicrobial peptides and synthetic copolymers using pyrroloquinoline quinone-loaded liposomes. Anal Biochem (2011) 0.75
Thoughts from the frontiers of science: the Gordon Research Conference on Drug Carriers in Medicine and Biology (August 20-25, 2006). Mol Pharm (2006) 0.75
Proline prodrug of melphalan, prophalan-L, demonstrates high therapeutic index in a murine melanoma model. Eur J Pharm Biopharm (2007) 0.75